149 related articles for article (PubMed ID: 26789203)
1. Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).
Erchegyi J; Wang L; Gulyas J; Samant M; Perrin MH; Lewis K; Miller C; Vaughan J; Donaldson C; Fischer W; Low W; Yakabi S; Karasawa H; Taché Y; Rivier C; Rivier J
J Med Chem; 2016 Feb; 59(3):854-66. PubMed ID: 26789203
[TBL] [Abstract][Full Text] [Related]
2. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
[TBL] [Abstract][Full Text] [Related]
3. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats.
Million M; Maillot C; Saunders P; Rivier J; Vale W; Taché Y
Am J Physiol Gastrointest Liver Physiol; 2002 Jan; 282(1):G34-40. PubMed ID: 11751155
[TBL] [Abstract][Full Text] [Related]
4. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2.
Martínez V; Wang L; Rivier JE; Vale W; Taché Y
J Pharmacol Exp Ther; 2002 May; 301(2):611-7. PubMed ID: 11961064
[TBL] [Abstract][Full Text] [Related]
5. Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice.
Martínez V; Wang L; Rivier J; Grigoriadis D; Taché Y
J Physiol; 2004 Apr; 556(Pt 1):221-34. PubMed ID: 14755002
[TBL] [Abstract][Full Text] [Related]
6. Peripheral urocortin delays gastric emptying: role of CRF receptor 2.
Nozu T; Martinez V; Rivier J; Taché Y
Am J Physiol; 1999 Apr; 276(4):G867-74. PubMed ID: 10198329
[TBL] [Abstract][Full Text] [Related]
7. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function.
Martínez V; Rivier J; Wang L; Taché Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):754-60. PubMed ID: 9023288
[TBL] [Abstract][Full Text] [Related]
8. Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2.
Wang L; Martínez V; Rivier JE; Taché Y
Am J Physiol Regul Integr Comp Physiol; 2001 Nov; 281(5):R1401-10. PubMed ID: 11641109
[TBL] [Abstract][Full Text] [Related]
9. CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist.
Macey DJ; Koob GF; Markou A
Brain Res; 2000 Jun; 866(1-2):82-91. PubMed ID: 10825483
[TBL] [Abstract][Full Text] [Related]
10. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL
J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963
[TBL] [Abstract][Full Text] [Related]
11. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
Bonk I; Rühmann A
Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments.
Brauns O; Liepold T; Radulovic J; Spiess J
Neuropharmacology; 2001 Sep; 41(4):507-16. PubMed ID: 11543771
[TBL] [Abstract][Full Text] [Related]
13. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats.
Maillot C; Million M; Wei JY; Gauthier A; Taché Y
Gastroenterology; 2000 Dec; 119(6):1569-79. PubMed ID: 11113078
[TBL] [Abstract][Full Text] [Related]
14. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
Martínez V; Rivier J; Taché Y
J Pharmacol Exp Ther; 1999 Aug; 290(2):629-34. PubMed ID: 10411571
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.
Rühmann A; Bonk I; Lin CR; Rosenfeld MG; Spiess J
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15264-9. PubMed ID: 9860957
[TBL] [Abstract][Full Text] [Related]
16. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.
Rivier JE; Rivier CL
Front Neuroendocrinol; 2014 Apr; 35(2):161-70. PubMed ID: 24269930
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
18. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
[TBL] [Abstract][Full Text] [Related]
19. Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF.
Jones DN; Kortekaas R; Hatcher PD; Middlemiss DN; White A; Hagan JJ
Eur J Pharmacol; 1999 Jun; 373(2-3):141-5. PubMed ID: 10414432
[TBL] [Abstract][Full Text] [Related]
20. Effects of urocortin, corticotropin-releasing factor (CRF) receptor agonist, and astressin, CRF receptor antagonist, on the sleep-wake pattern: analysis by radiotelemetry in conscious rats.
Uchida M; Suzuki M; Shimizu K
Biol Pharm Bull; 2007 Oct; 30(10):1895-7. PubMed ID: 17917258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
